Figure 1

Recommended dose modifications for brentuximab vedotin-associated toxicity

Toxicity	Grade 1	Grade 2	Grade 3	Grade 4
Sensory Neuropathy	Continue at same dose level	Continue at same dose level	Withhold BV until PN is ≤Grade 2, then reduce dose to 0.9 mg/kg and resume treatment; if already at 0.9 mg/kg, continue dosing at that dose.	Discontinue treatment with BV
Motor Neuropathy	Continue at same dose level	Reduce BV dose to 0.9 mg/kg and resume treatment	Discontinue treatment with BV	Discontinue treatment with BV
Non-hematologic (except peripheral neuropathy)	Continue at same dose level	Continue at same dose level	Withhold dose until toxicity is ≤ Grade 2 or has returned to baseline, then resume treatment at the same dose level[b].	Withhold dose until toxicity is ≤ Grade 2 or has returned to baseline, then reduce dose to 0.9 mg/kg and resume treatment, or discontinue at the discretion of the investigator [a,b,c].
Hematologic[d]	Continue at same dose level	Continue at same dose level	Withhold until toxicity resolves to ≤ Grade 2 or baseline, then resume treatment at the same dose level[e]. For Grade 3 or 4 neutropenia, growth factor support (G-CSF or GM-CSF) should be considered for subsequent cycles. If Grade 4 neutropenia recurs despite growth factor support, consider discontinuation or dose reduction to 0.9 mg/kg.	

a Dose reductions below 0.9 mg/kg are not allowed, and toxicities should be managed with dose delays.
b Subjects who develop Grade 3 or 4 electrolyte laboratory abnormalities may continue study treatment without interruption.
c Treatment should be discontinued for subjects who experience Grade 4 infusion-related reactions.
d Support with blood product transfusions allowed per institutional standard of care.
e Subjects who develop Grade 3 or 4 lymphopenia may continue study treatment without interruption.